COMPANY PROFILE

Biobot Surgical

Explore full profile

A company innovating the realm of robotic-assisted biopsy and treatment for prostate cancer

SingaporeFounded 2007Health Tech & Medtech

Valuation $100–500M Latest valuation · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Biobot Surgical

Biobot Surgical operates in the medical technology sector, specializing in robotic systems for prostate biopsies. The company's flagship product, the iSR'obot Mona Lisa, is a robotic transperineal prostate biopsy system that integrates MRI and ultrasound fusion technology. This system is designed to provide physicians with complete prostate coverage and accurate biopsy needle positioning, enhancing both precision and ease of use. The primary clients are healthcare providers, including hospitals and specialized clinics, who require advanced tools for diagnosing prostate cancer. Biobot Surgical's business model revolves around the sale and distribution of its robotic systems, along with associated software and support services. Revenue is generated through direct sales, distributorship agreements, and ongoing service contracts. The market for Biobot Surgical's products is global, with a focus on regions with high incidences of prostate cancer and advanced healthcare infrastructure.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2007
Headquarters: Singapore
Employees: 47
Open positions: None listed
Dealroom signal: 48.9/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Oncology, Medical Imaging, Spinout, Surgical Equipment, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Biobot Surgical.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Apr 2026	$16M	$120M	Kupa · astrid hill · ZIG Ventures · ClavystBio	↗
LATE VCOther financing	Apr 2025	$8.5M	$120M	ZIG Ventures · astrid hill	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Biobot Surgical website traffic

Latest recorded traffic for Biobot Surgical is 220 monthly website visits, down 85.3% over the last three months. Biobot Surgical's team grew 17.5% over the past year.

Latest monthly visits220 3-month web change-85.3% 1-year team growth+17.5%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MCMedical Devices CornerCreating a new chapter in minimally invasive surgery	Menlo Park, United States	Operational	14	—	—
TETechsoMedReal time Predictive visualization of true ablation damage	Rehovot, Israel	Operational
MEMethodsurgicalAI-powered surgical navigation software and planning tools for precision operations	Cleveland, United States	Operational
BMB dot MedicalUltra-compact proton therapy system for cancer treatment	Tokyo, Japan	Operational
HSHypervision SurgicalAI-powered hyperspectral imaging for real-time surgical guidance	London, United Kingdom	Operational
RSReveal SurgicalAI-driven molecular diagnostics platform to detect cancerous tissue in real time at the molecular level	Montreal, Canada	Operational
PBPulse BiosciencesProprietary nanosecond pulsed field ablation technology enabling non-thermal, cell-targeted treatment of cardiac arrhythmias and soft tissue disorders.	Hayward, United States	Operational
MIMicrimaDevelops and commercializes microwave radar breast imaging technology	Bristol, United Kingdom	Operational